Laboratory of Cellular Biology of Hypertension, Centre for Ecogenomic Models of Human Diseases, Centre de recherche, Centre hospitalier de l'Université de Montréal (CRCHUM), Technopôle Angus, 2901 rue Rachel est, bureau 314, Montreal, QC H1W 4A4, Canada.
Mol Cell Biochem. 2010 Jan;334(1-2):53-65. doi: 10.1007/s11010-009-0326-8. Epub 2009 Nov 25.
Studied for nearly 30 years for its ability to control many parameters, such as vascular smooth muscle cell relaxation, heart fibrosis, and kidney function, the natriuretic peptide (NP) system is now considered to be a key element in several other major metabolic pathways. After stimulation by NPs, natriuretic peptide receptors (NPR) convert GTP to the second messenger cGMP. In addition to its vasodilatory effects and natriuretic and diuretic functions, cGMP has been positively associated with fat cell function, apoptosis, and NPR expression/activity modulation. The NP system is also closely linked to metabolic syndrome (MetS) progression and obesity control. A new era is now on its way targeting the NP system to not only treat high blood pressure, but to also assist in the fight against the obesity pandemic. Here, we summarize recent data on the role of NPs in hypertension and MetS.
经过近 30 年的研究，发现利钠肽（NP）系统能够控制许多参数，如血管平滑肌细胞松弛、心脏纤维化和肾功能，因此被认为是几种其他主要代谢途径的关键因素。NP 刺激后，利钠肽受体（NPR）将 GTP 转化为第二信使 cGMP。除了具有血管扩张作用以及利钠和利尿功能外，cGMP 还与脂肪细胞功能、细胞凋亡和 NPR 表达/活性调节呈正相关。NP 系统还与代谢综合征（MetS）的进展和肥胖控制密切相关。目前，针对 NP 系统的一个新时代即将到来，其不仅可以用于治疗高血压，还可以用于对抗肥胖流行。在这里，我们总结了 NP 在高血压和 MetS 中的作用的最新数据。
